Becton Dickinson and Company (BDX) Shares are Up 2.46%

Becton Dickinson and Company (BDX) : Traders are bullish on Becton Dickinson and Company (BDX) as it has outperformed the S&P 500 by a wide margin of 2.86% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 1.91%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 2.46% in the last 1 week, and is up 0.78% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 0.28% and the 50-Day Moving Average is 0.48%.The 200 Day SMA reached 10.29% Becton, Dickinson and Company is up 6.07% in the last 3-month period. Year-to-Date the stock performance stands at 15.08%.


Becton Dickinson and Company (BDX) has been rated by 12 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $200 and the lowest price target forecast is $169. The average forecast of all the analysts is $185 and the expected standard deviation is $9.29.

For the current week, the company shares have a recommendation consensus of Buy. Becton Dickinson and Company (NYSE:BDX): stock was range-bound between the intraday low of $174.09 and the intraday high of $176.36 after having opened at $176.06 on Fridays session. The stock finally closed in the red at $176.06, a loss of -0.47%. The stock remained in the red for the whole trading day. The total traded volume was 998,066 shares. The stock failed to cross $176.36 in Fridays trading. The stocks closing price on Thursday was $176.02.

Becton, Dickinson and Company is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, life science researchers, clinical laboratories, pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Companys Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Companys BD Medical segment focuses on providing solutions to reduce the spread of infection, enhance diabetes treatment and advance drug delivery. The Companys BD Diagnostics provides products for the safe collection and transport of diagnostics specimens, as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers, clinical researchers, laboratory professionals and clinicians.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.